Democratic Report Alleges Trump Profited from Pharmaceutical Stocks Benefiting from Medicare Exemptions

According to a new report from congressional Democrats, investment in pharmaceutical companies held on behalf of President Donald Trump surged following his return to the White House last year. The report claims his portfolio saw millions of dollars in growth from firms that benefited from Republican-backed legislation shielding specific medications from Medicare price negotiations.

The Joint Economic Committee’s minority arm released the findings on Friday, noting that Trump’s pharmaceutical holdings rose from a reported peak of $1.7 million in 2024 to approximately $56.2 million by the end of 2025. The analysis suggests that up to $39.1 million of these holdings were in companies benefiting from Medicare negotiation exemptions established under the Republican tax and spending law of 2025.

Further examination of financial disclosures by committee Democrats revealed that Trump’s portfolio acquired up to $2.55 million in shares of pharmaceutical companies benefiting from these exemptions on three separate occasions prior to his signing of the legislation in July 2025. This included purchases totaling roughly $950,000 on July 1, 2025—the same day the Senate passed the bill. Additionally, the portfolio purchased approximately $1 million in AbbVie stock in August 2025, after the law took effect.

Since assuming office last year, the Republican president’s wealth has expanded through various business interests, many of which have intersected with his administration’s policy decisions. The White House has dismissed these claims, denying any ethical violations and accusing Democrats of attempting to manufacture conflicts of interest.

The report further contends that the exemption policy could result in Medicare beneficiaries paying thousands of dollars more for critical medications, such as certain cancer treatments, than they would under a standard Medicare negotiation framework.

These allegations arrive as President Trump maintains that reducing prescription drug costs is a pillar of his healthcare agenda. While his administration claims to be securing deals to increase affordability, drug pricing remains influenced by a complex array of economic factors.

Recent data from the Associated Press-NORC Center for Public Affairs Research indicates that a majority of Americans believe the president is profiting from his office in ways that are unethical or illegal, suggesting a public perception that his personal wealth takes precedence over constituent needs.

Democratic Senator Maggie Hassan, leader of the Joint Economic Committee’s minority arm, characterized the report’s findings as “outrageous,” accusing the president of prioritizing personal gain at the expense of the American public.

In response, White House spokesperson Davis Ingle stated that Trump’s stock and bond portfolio is managed independently by third-party financial institutions, denying any conflict of interest.

“Neither President Trump nor any member of his family has any ability to direct, influence, or provide input regarding how the portfolio is invested or when investments are bought or sold,” Ingle said in an official statement.

Under the previous Democratic administration of President Joe Biden, Medicare was granted the authority to negotiate prices for several high-cost prescription drugs for the first time. However, the 2025 Republican tax and spending bill expanded “orphan drug” exemptions. According to the healthcare research nonprofit KFF, this move delayed or entirely excluded certain expensive medications from negotiations by classifying them as treatments for rare diseases.

While proponents argue that these exemptions incentivize the development of treatments for rare conditions, critics contend they allow manufacturers of high-revenue “blockbuster” drugs to bypass negotiations that would lower costs for Medicare and its participants.

The report estimates that Medicare patients using cancer drugs such as Merck’s pembrolizumab (Keytruda) and Bristol Myers Squibb’s nivolumab (Opdivo) could face annual costs roughly $5,000 higher than they would if Medicare had negotiated those prices. Trump’s portfolio contains holdings in both companies.

The report concluded by noting that Trump’s portfolio remained active in the pharmaceutical sector throughout the first eight months of 2026, adding as much as $3.5 million in sector-specific stock wealth.

Source link